Idera Pharmaceuticals, Inc. Announces Issuance of US Patent for Novel Oligonucleotide Compositions Targeted to Toll-like Receptors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the issuance of US patent 7,276,489 (the ‘489 patent) for novel oligonucleotide compositions. The claims of this patent, entitled “Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds By Optimal Presentation of 5’ Ends,” cover oligonucleotide compositions in which two oligonucleotides are attached together through their 3’ ends and contain various synthetic immune stimulatory motifs. These claims provide additional protection for the Company’s TLR9-targeted compounds, including its two lead product candidates, IMO-2055 and IMO-2125.

MORE ON THIS TOPIC